Biomea Fusion, Inc. Operating Lease, Expense
Biomea Fusion, Inc. (BMEA) reported Operating Lease, Expense of $400.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2021-11-03
- Biomea Fusion, Inc. operating lease, expense for the quarter ending 2021-09-30 was $400.00K, a 534.92% increase year-over-year.
- Biomea Fusion, Inc. operating lease, expense for the quarter ending 2021-06-30 was $319.00K, a 5216.67% increase year-over-year.
- Biomea Fusion, Inc. operating lease, expense for the quarter ending 2021-03-31 was $141.16K, a 551.68% increase year-over-year.
- Biomea Fusion, Inc. operating lease, expense for the quarter ending 2020-09-30 was $63.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month |
|---|---|---|---|
| 2021-09-30 | $400.00K 10-Q · filed 2021-11-03 | $719.00K derived: sum of 2 quarters · filed 2021-11-03 | $800.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $319.00K 10-Q · filed 2021-08-11 | $460.00K 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $141.16K 10-Q · filed 2021-05-27 | ||
| 2020-09-30 | $63.00K 10-Q · filed 2021-11-03 | $69.00K derived: sum of 2 quarters · filed 2021-11-03 | $91.00K 10-Q · filed 2021-11-03 |
| 2020-06-30 | $6.00K 10-Q · filed 2021-08-11 | $28.00K 10-Q · filed 2021-08-11 | |
| 2020-03-31 | $21.66K 10-Q · filed 2021-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |